E85.82

Clinical Causes: Age-related changes leading to increased production of transthyretin proteins Degeneration of transthyretin proteins into misfolded amyloid fibrils No known genetic mutations in wild-type form, unlike hereditary amyloidosis Other potential contributing factors include ongoing oxidative stress and cellular aging

Key Symptoms: Progressive heart failure symptoms, such as fatigue, shortness of breath, and swelling Conduction abnormalities leading to arrhythmias Experience of persistent dizziness or fainting episodes Involvement of peripheral nerves causing numbness, tingling, or weakness Unexplained weight loss and muscle weakness Potential kidney impairment in some cases Carpal tunnel syndrome due to amyloid deposits in connective tissues

Diagnosis Path: Diagnosing wild-type transthyretin amyloidosis involves multiple assessments. Physicians may use imaging tests such as echocardiograms and cardiac MRI to evaluate organ damage. Tissue biopsy, often from the abdominal fat pad or affected organs, can confirm amyloid deposits through special staining techniques. Additional tests include blood and urine studies to rule out other causes and genetic testing to distinguish between wild-type and hereditary forms. Advanced techniques like mass spectrometry can identify the specific type of amyloid proteins present.

Treatment Protocols: Treatment options focus on managing symptoms and slowing disease progression. Medications like tafamidis and diflunisal have shown promise in stabilizing transthyretin proteins, reducing amyloid formation. Heart failure treatments may be needed to address cardiac symptoms. Supportive care may involve managing arrhythmias, improving quality of life, and monitoring organ health regularly. In select cases, liver transplantation might be considered for hereditary variants, but it is generally not used for wild-type amyloidosis. Ongoing research aims to discover better therapies and diagnostic tools.